What Ra Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| New Enterprise Associates 13 Lp | 10% owner | Apr 02 | Disposition to Issuer · D | −6,135,234 | — | — | 0 |
| Ra Capital MANAGEMENT, L.p. | Director | Apr 02 | Disposition to Issuer · D | −4,858,260 | $48.00 | −$233M | 0 |
| Shah Rajeev M. | Director | Apr 02 | Disposition to Issuer · D | −4,858,260 | $48.00 | −$233M | 0 |
| Lubner David Charles | Executive VP and CFO | Apr 02 | Disposition to Issuer · D | −15,622 | $48.00 | −$750K | 0 |
| Treco Douglas A | President and CEO | Apr 02 | Disposition to Issuer · D | −234,707 | $48.00 | −$11.3M | 0 |
| Read Simon | Chief Scientific Officer | Apr 02 | Disposition to Issuer · D | −12,595 | $48.00 | −$605K | 0 |
| Ricardo Alonso | See Remarks | Apr 02 | Disposition to Issuer · D | −2,973 | $48.00 | −$143K | 0 |
| King John C | Chief Commercial Officer | Apr 02 | Disposition to Issuer · D | −10,823 | $48.00 | −$520K | 0 |
| Farzaneh-Far Ramin | Chief Medical Officer | Apr 02 | Disposition to Issuer · D | −14,492 | $48.00 | −$696K | 0 |
| Ricardo Alonso | See Remarks | Mar 17 | Open-market sale · S | −2,288 | $44.25 | −$101K | 0 |
| Farzaneh-Far Ramin | Chief Medical Officer | Mar 16 | Open-market sale · S | −10,595 | $45.16 | −$479K | 7,132 |
| Farzaneh-Far Ramin | Chief Medical Officer | Mar 16 | Exercise / conversion · M | +9,206 | $5.60 | +$51.6K | 17,727 |
| Farzaneh-Far Ramin | Chief Medical Officer | Mar 16 | Exercise / conversion · M | +1,389 | $5.60 | +$7.78K | 8,521 |
| Farzaneh-Far Ramin | Chief Medical Officer | Feb 18 | Open-market sale · S | −10,595 | $46.61 | −$494K | 7,132 |
| Farzaneh-Far Ramin | Chief Medical Officer | Feb 18 | Exercise / conversion · M | +9,206 | $5.60 | +$51.6K | 17,727 |
| Farzaneh-Far Ramin | Chief Medical Officer | Feb 18 | Exercise / conversion · M | +1,389 | $5.60 | +$7.78K | 8,521 |
| Ricardo Alonso | See Remarks | Jan 17 | Open-market sale · S | −2,285 | $47.02 | −$107K | 2,288 |
| Farzaneh-Far Ramin | Chief Medical Officer | Jan 15 | Open-market sale · S | −10,595 | $46.95 | −$497K | 7,132 |
| Farzaneh-Far Ramin | Chief Medical Officer | Jan 15 | Exercise / conversion · M | +9,206 | $5.60 | +$51.6K | 17,727 |
| Farzaneh-Far Ramin | Chief Medical Officer | Jan 15 | Exercise / conversion · M | +1,389 | $5.60 | +$7.78K | 8,521 |
Loading...